Obiettivo Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been higher and the growing proportion of drug-resistant TB is threatening control strategies both in the developing and developed world, Eastern Europe being a particularly worrying point in case. The anTBiotic consortium aims to fuel the long-term TB clinical pipeline while immediately offering new options to clinicians when confronted with multidrug-resistant (MDR)-TB. More specifically, the proposed studies aim to: a) Establish the proof of concept of anti-TB efficacy in humans of a pioneering, first-in-class, low-dose GSK oxaborole clinical drug candidate; b) Identify a combination of β-lactam antibiotics suitable for the treatment of MDR TB orally or as a once daily intravenous or intramuscular application and c) Incorporate the best β-lactam combination into an explorative salvage regimen for untreatable patients with extensively drug-resistant TB The anti-TB activity in humans will be established in a two-week EBA clinical studies that combine established (CFU, TTP) and new clinical markers (biomarkers, PET/CT). These datasets will help ascertain anti-TB efficacy in humans and generate confidence on their validity in longer-term drug combination trials. A variety of modelling approaches to predict optimal dosing will be used. Finally, we intend to use at least one of these novel anti-TB entities as part of a pioneering, non-controlled clinical trial in highly drug resistant subjects in Europe and South Africa. This final clinical intervention will hopefully be of immediate benefit to drug-resistant patients in the EU and elsewhere in addition to generating a strong precedent for further adoption worldwide. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Parole chiave Tuberculosis Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) SC1-PM-09-2016 - New therapies for chronic diseases Invito a presentare proposte H2020-SC1-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SC1-2016-RTD Meccanismo di finanziamento RIA - Research and Innovation action Coordinatore GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL Contribution nette de l'UE € 704 870,67 Indirizzo C/ SEVERO OCHOA NUMERO 2 PARQUE TECNOLOGICO DE MAD 28760 TRES CANTOS MADRID Spagna Mostra sulla mappa Regione Comunidad de Madrid Comunidad de Madrid Madrid Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 704 870,67 Partecipanti (4) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET Norvegia Contribution nette de l'UE € 644 072,50 Indirizzo HANSINE HANSENS VEG 14 9019 Tromso Mostra sulla mappa Regione Norge Nord-Norge Troms og Finnmark Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 644 072,50 FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM Germania Contribution nette de l'UE € 1 242 417,00 Indirizzo PARKALLEE 1-40 23845 Borstel Mostra sulla mappa Regione Schleswig-Holstein Schleswig-Holstein Segeberg Tipo di attività Research Organisations Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 242 417,00 UNIVERSITY OF CAPE TOWN Sud Africa Contribution nette de l'UE € 209 953,75 Indirizzo PRIVATE BAG X3 7701 Rondebosch Mostra sulla mappa Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 209 953,75 TASK FOUNDATION NPC Sud Africa Contribution nette de l'UE € 3 018 102,08 Indirizzo M2 KARL BREMER HOSPITAL MIKE PIENAAR BOULEVARD BELLEVILLE 7530 Cape Town Mostra sulla mappa Tipo di attività Other Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 3 018 102,08